Global Hemophilia
Treatment Market, by Product Type (Plasma Derived Coagulation Factor
Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytic
Agents, and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$
11,474.3 million in 2018, and is expected to exhibit a CAGR of 5.9%, over the
forecast period (2019-2027).
Increasing incidence & prevalence
of hemophilia or factor VIII deficiency is expected to drive growth of the
hemophilia treatment market over the forecast period. For instance, according
to the World Federation of Hemophilia (WFH), around 440,000 people across the
globe were suffering from hemophilia, out of which around 173,000 people were
diagnosed with hemophilia A or B in 2017. Major players are focused on product
launches and approvals owing to the rising demand for hemophilia treatment. For
instance, in March 2016, the U.S. Food and Drug Administration approved
Kedrion’s Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human)
with Mix2Vial, for treatment of factor VIII deficiency. Moreover, in May 2018,
Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche Group launched its
anticoagulation factor IXa/X humanized biospecific monoclonal
antibody/coagulation factor VIII substitute, HEMLIBRA, for routine prophylaxis,
to prevent or reduce the frequency of bleeding episodes in patients with
congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2012
Browse 35 Market Data Tables and
21 Figures spread through 188 Pages and in-depth TOC on 'Hemophilia Treatment
Market’- global forecast to 2027, by Product Type (Plasma Derived Coagulation
Factor Concentrates, Recombinant Coagulation Factor Concentrates,
Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia
A, Hemophilia B, and Hemophilia C), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa)'
Asia Pacific is expected to offer
lucrative growth opportunities for players operating in the hemophilia
treatment market owing to the favorable regulatory scenario and guidelines by
government authorities, which, in turn, is expected to fuel growth of the
market over the forecast period. For instance, according to the World
Hemophilia Foundation’s 2015 report of National Tenders for Purchase of
Clotting Factor Concentrates, According to the Chinese Ministry of Health
report 2012, in China, outpatient hemophilia treatment is covered by health
insurance schemes in more than 80% of the cities in China, with reimbursement
caps and patient co-pay requirements more than 50%. Moreover, annual
reimbursement is usually capped below US$ 16,000. Moreover, several major
players in the market are focusing on collaborations with the aim of developing
novel therapies for factor VIII deficiency treatment, which is expected to
facilitate growth of the market over the forecast period. For instance, in
August 2018, RCSI, a Dublin-based international health sciences institution,
and Bayer AG entered a research collaboration to develop new treatment options
for people with severe hemophilia. Furthermore, in May 2017, Sangamo
Therapeutics, Inc., a genomic medicine company, and Pfizer Inc., entered a
global collaboration and license agreement for development and
commercialization of a gene therapy-based product for treatment of hemophilia
A.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/hemophilia-treatment-market-2012
Key Takeaways of the Hemophilia
Treatment Market:
The global hemophilia treatment
market is expected to exhibit a CAGR of 5.9% over the forecast period owing to
rising incidence of hemophilia, and approvals and launch of novel products. For
instance, according to the National Hemophilia Foundation’s 2018 report,
globally one in 10,000 people are born with hemophilia A due to deficiency of
clotting factor VIII, and one in 50,000 people are born with hemophilia B due
to lack of clotting factor IX.
Among product type, the plasma
derived coagulation factor concentrates segment held a dominant position in the
hemophilia treatment market in 2018 owing to cost effectiveness. For instance,
according to the reports published by the World Federation of Hemophilia in
2016, the demand for plasma derived coagulation factors is high compared to
recombinant coagulation concentrates due to their affordability and easy availability
in emerging economies.
Companies operating in the global
hemophilia treatment market include Takeda Pharmaceutical Co., Ltd., Sanofi
S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc.,
Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo
Nordisk A/S, F. Hoffmann-La Roche AG.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2012
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment